{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:01:32Z","timestamp":1791241292782,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.msard.2023.104880","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T01:25:29Z","timestamp":1689125129000},"page":"104880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting"],"prefix":"10.1016","volume":"77","author":[{"given":"Beng\u00fc","family":"Altunan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7702-8437","authenticated-orcid":false,"given":"Aysun","family":"\u00dcnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcsn\u00fc","family":"Efendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesrure","family":"K\u00f6seo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Terzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilcan","family":"Kotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Tamam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cavit","family":"Boz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"G\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer Faruk","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Altunrende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Belgin","family":"Balc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilda","family":"Turgut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Ak\u00e7al\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadriye A\u011fan","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek \u0130nce","family":"G\u00fcnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulin","family":"Sunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayhan","family":"Bing\u00f6l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104880_bib0001","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40263-014-0185-z","article-title":"Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait","volume":"28","author":"AL-Hashel","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2023.104880_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230846","article-title":"Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study","volume":"15","author":"Barrero","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2023.104880_bib0004","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/0897190017725984","article-title":"Development of Glatopa\u00ae (Glatiramer Acetate): the first FDA-approved generic disease-modifying therapy for relapsing forms of multiple sclerosis","volume":"163","author":"Bell","year":"2018","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.msard.2023.104880_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0267346","article-title":"The safety and efficacy of fingolimod: real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary","volume":"17","author":"Biernacki","year":"2022","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2023.104880_bib0006","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1038\/s41598-021-83220-1","article-title":"Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study","volume":"11","author":"Bourdin","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2023.104880_bib0007","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1177\/13524585221116269","article-title":"Use of follow-on disease-modifying treatments for multiple sclerosis: consensus recommendations","volume":"28","author":"Brownlee","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104880_bib0008","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104880_bib0009","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2147\/DDDT.S66398","article-title":"Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod","volume":"25","author":"Correale","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.msard.2023.104880_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.msard.2016.01.003","article-title":"The effectiveness of fingolimod in a Portuguese real-world population","volume":"6","author":"Correia","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104880_bib0011","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1177\/13524585211000280","article-title":"Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis","volume":"27","author":"Cree","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104880_bib0012","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WCO.0000000000000094","article-title":"Relapsing and progressive forms of multiple sclerosis: insights from pathology","volume":"27","author":"Dutta","year":"2014","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2023.104880_bib0013","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2147\/PPA.S270557","article-title":"Comparative adherence trajectories of oral fingolimod and injectable disease modifying agents in multiple sclerosis","volume":"14","author":"Earla","year":"2020","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2023.104880_bib0014","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.msard.2014.06.005","article-title":"Outcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis","volume":"3","author":"Fox","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104880_bib0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/DHPS.S69640","article-title":"Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis","volume":"7","author":"Gajofatto","year":"2015","journal-title":"Drug Healthc. Patient Saf."},{"key":"10.1016\/j.msard.2023.104880_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.07.011","article-title":"Early initiation of fingolimod reduces the rate of severe relapses over the long term: post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies","volume":"36","author":"Haas","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104880_bib0017","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/PPA.S41992","article-title":"A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod","volume":"7","author":"Hanson","year":"2013","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2023.104880_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.34627","article-title":"Comparison of dimethyl fumarate vs fingolimod and rituximab vs natalizumab for treatment of multiple sclerosis","volume":"4","author":"Hou","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.msard.2023.104880_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102346","article-title":"Switching to fingolimod in PREFERMS: effect of treatment history and na\u00efvety on clinical, MRI and treatment satisfaction outcomes\u2730","volume":"45","author":"Hunter","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104880_bib0020","first-page":"844","article-title":"Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 Year","volume":"23","author":"Johnson","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.msard.2023.104880_bib0021","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104880_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102416","article-title":"Long-term outcome in multiple sclerosis patients treated with fingolimod","volume":"45","author":"Lattanzi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104880_bib0023","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.104880_bib0024","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2147\/PPA.S144021","article-title":"Treatment satisfaction and quality of life in patients treated with fingolimod","volume":"12","author":"M\u00e9ki\u00e8s","year":"2018","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2023.104880_bib0025","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1177\/1352458519845106","article-title":"The emergence of follow-on disease-modifying therapies for multiple sclerosis","volume":"25","author":"Moss","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104880_bib0027","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40120-019-0145-0","article-title":"Biosimilar drugs for multiple sclerosis: an unmet international need or a regulatory risk?","volume":"8","author":"Rivera","year":"2019","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2023.104880_bib0028","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3389\/fneur.2017.00183","article-title":"Efficacy and safety of fingolimod in daily practice: experience of an academic MS French center","volume":"8","author":"Roux","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2023.104880_bib0029","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ene.15121","article-title":"A real-world study of alemtuzumab in a cohort of Italian patients","volume":"29","author":"Russo","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2023.104880_bib0030","article-title":"Disease-modifying therapies in multiple sclerosis in Latin America","volume":"3","author":"Skromne-Eisenberg","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2023.104880_bib0031","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40261-016-0471-2","article-title":"Real-world outcomes in fingolimod-treated patients with multiple sclerosis in the Czech Republic: results from the 12-Month GOLEMS study","volume":"37","author":"Tich\u00e1","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.msard.2023.104880_bib0032","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000514828","article-title":"Long-term effectiveness of fingolimod for multiple sclerosis in a real-world clinical setting","volume":"84","author":"Uzunk\u00f6pr\u00fc","year":"2021","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.msard.2023.104880_bib0033","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1007\/s00415-021-10931-w","article-title":"Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany","volume":"269","author":"Ziemssen","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104880_bib0034","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12883-015-0342-0","article-title":"The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice","volume":"15","author":"Ziemssen","year":"2015","journal-title":"BMC Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823003814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823003814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T14:10:00Z","timestamp":1737641400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823003814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":32,"alternative-id":["S2211034823003814"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104880","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104880"}}